UPLC-Q-TOF/MS-Based Serum Metabolomics Reveals Potential Anti-tumor Mechanism of Banxia Xiexin Decoction in Colorectal Cancer Mice  

作　　者：YUE Yin-zi LI Ming-xuan WANG Xiao-hui QIN Yuan-yuan WANG Ya-hui TAN Jin-hua SU Lian-lin YAN Shuai 

机构地区：[1]Department of General Surgery,Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Suzhou,215009,China [2]School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing,210023,China [3]Department of General Surgery,Bayinguoleng Mongolian Autonomous Prefecture People’s Hospital,Xinjiang Uygur Autonomous Region,Korla,841000,China [4]Department of Pharmacy,Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Suzhou,215009,China [5]Department of Anorectal Surgery,Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Suzhou,215009,China

出　　处：《Chinese Journal of Integrative Medicine》2024年第7期623-632,共10页中国结合医学杂志（英文版）

基　　金：Supported by the Natural Science Foundation of Nanjing University of Chinese Medicine(No.XZR2020038);Science and Technology Innovation Project of Suzhou Medical and Health Care(No.SKJY2021136);Fifth Batch of Gusu Health Personnel Training Project in Suzhou(No.GSWS2020085)。

摘　　要：Objective To clarify the potential mechanism of Banxia Xiexin Decoction(BXD)on colorectal cancer(CRC)from the perspective of metabolomics.Methods Forty male C57BL/6 mice were randomly divided into normal control(NC),azoxymethane/dextran sulfate sodium(AOM/DSS)model,low-dose BXD(L-BXD),high-dose BXD(H-BXD)and mesalamine(MS)groups according to a random number table,8 mice in each group.Colorectal cancer model was induced by AOM/DSS.BXD was administered daily at doses of 3.915(L-BXD)and 15.66 g/kg(H-BXD)by gavage for consecutive 21 days,and 100 mg/kg MS was used as positive control.Following the entire modeling cycle,colon length of mice was measured and quantity of colorectal tumors were counted.The spleen and thymus index were determined by calculating the spleen/thymus weight to body weight.Inflammatory cytokine and changes of serum metabolites were analyzed by enzyme-linked immunosorbent assay kits and ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry(UPLC-Q/TOF-MS),respectively.Results Notably,BXD supplementation protected against weight loss,mitigated tumor formation,and diminished histologic damage in mice treated with AOM/DSS(P<0.05 or P<0.01).Moreover,BXD suppressed expression of serum inflammatory enzymes,and improved the spleen and thymus index(P<0.05).Compared with the normal group,102 kinds of differential metabolites were screened in the AOM/DSS group,including 48 potential biomarkers,involving 18 main metabolic pathways.Totally 18 potential biomarkers related to CRC were identified,and the anti-CRC mechanism of BXD was closely related to D-glutamine and D-glutamate metabolism,phenylalanine,tyrosine and tryptophan biosynthesis,arginine biosynthesis,nitrogen metabolism and so on.Conclusion BXD exerts partial protective effects on AOM/DSS-induced CRC by reducing inflammation,protecting organism immunity ability,and regulating amino acid metabolism.

关 键 词：colorectal cancer metabolomics ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry AZOXYMETHANE dextran sulfate sodium Banxia Xiexin Decoction Chinese medicine 

分 类 号：R285[医药卫生—中药学]